TIDMABC
RNS Number : 0180D
ABCAM PLC
17 October 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION
IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH
JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED
HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION
WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
ABCAM PLC
Proposed Cancellation of Admission of Ordinary Shares to Trading
on AIM
and
Notice of General Meeting
Notice of General Meeting to be held on 11 November 2022
17 October 2022
CAMBRIDGE, Abcam plc, AIM:ABC and Nasdaq:ABCM ("Abcam" or the
"Company"), a global leader in the supply of life science research
tools, today announces:
- the Company's intention to cancel the admission of its
ordinary shares of nominal value 0.02 pence each (the "Ordinary
Shares") to trading on AIM (the "AIM Delisting"), subject to
shareholder approval, with effect from 14 December 2022. Subject to
shareholder approval, the Company's last day of trading on AIM will
be 13 December 2022. Abcam will retain the listing on the Nasdaq
Global Select Market ("Nasdaq") of American Depositary Shares, each
representing one Ordinary Share (the "ADSs"), under ticker symbol
"ABCM", and all public trading of securities in the Company will
take place on that exchange. Existing holders of ADSs not also
holding Ordinary Shares do not need to take any action in relation
to the AIM Delisting; and
- the posting of a circular to Abcam shareholders (the
"Circular"), which contains further information on the AIM
Delisting and the process to deposit Ordinary Shares for delivery
of ADSs and notice of a general meeting to be held on 11 November
2022 at Discovery Drive, Cambridge Biomedical Campus, Cambridge,
CB2 0AX, United Kingdom at 2.00 p.m. (London time) (the "General
Meeting") at which shareholder approval will be sought, inter alia,
for the AIM Delisting.
The Proposed AIM Delisting and the General Meeting
Highlights
-- Following the AIM Delisting, the Company's ADSs will remain
listed on Nasdaq, which will become the primary trading venue for
its equity securities, and all public trading of securities in the
Company will take place on that exchange.
-- The board of directors of the Company (the "Board" and the
"Directors") expects that the AIM Delisting and moving to a sole
listing on Nasdaq will further enhance the liquidity of trading in
the Company's securities by combining on Nasdaq the volume of
transactions from both Nasdaq and AIM.
-- The Company is providing an opportunity for shareholders to
deposit their Ordinary Shares with the Company's ADS depositary in
exchange for delivery of ADSs, without cost, in connection with the
AIM Delisting whether prior, on, or subsequent to 14 December 2022
(being the date on which the AIM Delisting takes effect).
Alan Hirzel, Chief Executive Officer of Abcam, said :
"This proposed listing change will make it possible for Abcam to
attract more investors to our global business. With the change, we
see a path to creating value by increasing stock trading liquidity
for our current and potential shareholders. We are grateful to have
the support from current shareholders for our proposal and look
forward to attracting new life science investors to the Abcam
story."
The Company will today be posting the Circular to shareholders,
which will set out further information on the process to deposit
Ordinary Shares for delivery of ADSs, including personalised forms
for those holders of certificated Ordinary Shares who wish to
deposit their Ordinary Shares for delivery of ADSs, as well as
containing the notice of General Meeting. Copies will also be
available on Abcam's website at https://corporate.abcam.com/ .
Background
The Company was incorporated in 1998 and its Ordinary Shares
have been admitted to trading on the AIM market of the London Stock
Exchange since 2005. In October 2020, the Company completed a
direct listing of ADSs representing 10,287,000 Ordinary Shares on
Nasdaq. The listing of the ADSs on Nasdaq provided the Company with
access to a broader US investor base, in particular from long-term
life science investors, access to deeper US capital pools, and
provided additional liquidity for the Company's shareholders.
Since the listing of the ADSs on Nasdaq in October 2020, the
number of Ordinary Shares, represented by ADSs, that are tradeable
on Nasdaq has approximately tripled. As at 12 October 2022, being
the last practicable date prior to the date of the Circular,
approximately 14 per cent. of the Company's Ordinary Shares are
represented by ADSs tradeable on Nasdaq. While only 14 per cent. of
our Ordinary Shares trade through ADSs in the US market, it
represents approximately 24 per cent. of the overall average daily
volume of the Ordinary Shares on both AIM and Nasdaq over the past
one month to 12 October 2022.
The Company is not expecting any significant operating changes
as a result of the AIM Delisting and is not proposing to alter its
domicile or to relocate its global headquarters from Cambridge in
the UK.
All shareholders who have not already deposited their Ordinary
Shares for delivery of ADSs are currently able to do so at any
time. Affiliates of the Company who deposit their ordinary shares
may be subject to limitations on resale of ADSs under U.S.
securities laws.
The AIM Rules for Companies require that, unless the London
Stock Exchange otherwise agrees, the cancellation of a company's
shares from trading on AIM requires the consent of not less than 75
per cent. of votes cast by its shareholders voting in a general
meeting. Accordingly, the Board is seeking shareholder approval for
the proposed AIM Delisting.
Reasons for the AIM Delisting
The Board has resolved, subject to shareholder approval, to
implement the AIM Delisting for the following reasons:
-- The Board expects that delisting from AIM and maintaining a
sole listing of ADSs representing the Company's Ordinary Shares on
Nasdaq will further enhance the liquidity of trading in the
Company's securities by combining on Nasdaq the volume of
transactions from both markets (Nasdaq and AIM).
-- Delisting from AIM would remove certain complexities and
duplication that comes with administering two listing regimes. For
example, by simplifying shareholder communications and compliance
with regulatory requirements and by reducing associated costs and
demand for internal resources.
-- The Board expects that a Nasdaq-only listing structure will
continue to attract the appropriate investor base and investment
style, maximizing the Company's ability to access deeper pools of
capital, reflecting the Company's global presence and aligning more
closely with its peers in the global life science tools
industry.
-- The Company will continue to attract research analyst
coverage from industry participants knowledgeable of the global
life science tools industry, driven by their current research of
peer companies (many of which are Nasdaq-listed).
-- In addition, the Company maintains the option to use
Nasdaq-listed ADSs as transaction consideration, providing more
flexible financing for future acquisitions.
Accordingly, the Directors believe that it is in the best
interests of the Company and its shareholders as a whole to cancel
the admission of the Company's Ordinary Shares to trading on
AIM.
The Company is providing an opportunity for shareholders to
deposit their Ordinary Shares with the Depositary in exchange for
delivery of ADSs, without cost, in connection with the AIM
Delisting prior to or on 14 December 2022 (being the date on which
the AIM Delisting takes effect).
Effect of the AIM Delisting
If the Resolution is passed at the General Meeting, shareholders
will no longer be able to buy and sell Ordinary Shares on AIM after
13 December 2022.
The section 'Information for holders of Ordinary Shares' below
provides more detail on the process of depositing Ordinary Shares
for delivery of ADSs.
As a company incorporated in England and Wales, the Company will
continue to be subject to the requirements of the Companies Act
2006.
Following the AIM Delisting taking effect, the Company will no
longer be subject to the AIM Rules for Companies or be required to
retain the services of an independent nominated adviser. The
Company will also no longer be required to comply with the
continuing obligations set out in the Disclosure Guidance and
Transparency Rules (the "DTRs") of the Financial Conduct Authority
(the "FCA") or, provided the Company's securities remain outside
the scope of the regulation, UK MAR. In addition, the Company and
its shareholders will no longer be subject to the provisions of the
DTRs relating to the disclosure of changes in significant
shareholdings in the Company. The Company will, however, continue
to comply with all regulatory requirements for the Nasdaq listing
of ADSs, including all applicable rules and regulations of the
SEC.
Shareholders who continue to hold Ordinary Shares following the
AIM Delisting will continue to be notified in writing of the
availability of key documents on the Company's website, including
publication of annual reports and annual general meeting
documentation. Holders of ADSs will be able to continue to access
all such information via the Company's website. Holders of Ordinary
Shares and ADSs will both be eligible to receive any future
dividends that may be declared.
Details of the application of the City Code to the Company
following the AIM Delisting are set out below.
Following the announcement, and effective date, of the AIM
Delisting, holders of Ordinary Shares may choose to sell or
otherwise dispose of their Ordinary Shares rather than deposit such
Ordinary Shares for delivery of ADSs. However, if significant, any
such sales of Ordinary Shares could have a negative effect on the
value of the Ordinary Shares, as well as the trading price of the
ADSs, which could inhibit other shareholders' ability to sell or
dispose of their Ordinary Shares at current trading prices.
Information for holders of Ordinary Shares
If the Resolution is passed at the General Meeting, the
Company's Ordinary Shares will continue to be traded on AIM until
market close (4.30 p.m. London time) on 13 December 2022.
Thereafter, holders of Ordinary Shares can still hold the Ordinary
Shares, but there will be no public market in the United Kingdom on
which the Ordinary Shares can be traded, and the Ordinary Shares
will not be tradeable on Nasdaq in this form.
To sell Ordinary Shares on Nasdaq following the AIM Delisting,
shareholders would need to deposit their Ordinary Shares for
delivery of ADSs. Each ADS represents one Ordinary Share. This
deposit can be made at any time, including before the AIM
Delisting, subject in all cases to the provisions of, and the
limitations set forth in, the Deposit Agreement. A copy of the
Deposit Agreement has been filed as Exhibit 2.1 to the Company's
Annual Report on Form 20-F filed with the SEC on 14 March 2022. You
may obtain a copy of the Deposit Agreement from the SEC's website
(www.sec.gov). Please refer to Commission File Number 333-249526
when retrieving such copy.
The Board considers that shareholders should consider depositing
their Ordinary Shares for delivery of ADSs prior to the AIM
Delisting on 14 December 2022 for the following reasons:
-- For those shareholders who hold their Ordinary Shares in
certificated form and wish to deposit their Ordinary Shares for
delivery of ADSs, the Company's Receiving Agent, Equiniti, will
facilitate, on the Company's behalf, a block transfer process.
Shareholders who hold their Ordinary Shares in certificated form
will find enclosed a Certificated Transfer Form for use if they
wish to deposit their Ordinary Shares for delivery of ADSs. Subject
to the requisite documents being returned to Equiniti by the
required deadline (being 5.00 p.m. UK time on 1 December 2022),
Equiniti will arrange for the relevant Ordinary Shares to be
transferred to and through Equiniti's CREST account to the CREST
account of the Custodian, which has been appointed by the
Depositary to hold the Ordinary Shares upon deposit, so that the
Depositary can arrange to deliver the corresponding number of ADSs.
The Custodian, on behalf of the Depositary, will hold all deposited
Ordinary Shares in a custody account for the benefit of the holders
and beneficial owners of ADSs.
-- Shareholders who elect to deposit their Ordinary Shares for
delivery of ADSs prior to the AIM Delisting will not incur a UK
stamp duty, or SDRT, charge. However, it is expected that
shareholders who elect to deposit their Ordinary Shares for
delivery of ADSs following the AIM Delisting will incur a stamp
duty, or SDRT, charge, at a rate of 1.5 per cent. of the market
value of the Ordinary Shares being deposited, to the UK taxation
authority, HMRC.
-- Ordinarily, shareholders who deposit their Ordinary Shares
for delivery of ADSs are charged an ADS issuance fee, by the
Depositary, of up to $0.05 per ADS. However, no ADS issuance fees
will be charged to shareholders who elect to deposit their Ordinary
Shares in connection with the AIM Delisting on or prior to 14
December 2022 (or such other date as when the AIM Delisting takes
effect).
Shareholders who do not elect to participate in the block
transfer process can utilise the services of a broker who is able
to facilitate deposits of Ordinary Shares at the shareholder's
convenience.
Shareholders whose Ordinary Shares are held in uncertificated
form in CREST and who wish to deposit their Ordinary Shares for
delivery of ADSs, should contact their broker without delay to
request that their Ordinary Shares are deposited. The Company
advises holders of Ordinary Shares to seek independent financial
advice regarding the AIM Delisting and the deposit of their
Ordinary Shares for delivery of ADSs.
Information on the process to deposit Ordinary Shares for
delivery of ADSs and the forms to be completed accompany the
Circular. The information and contacts at the Company's Receiving
Agent, Equiniti, in respect of completion of the Certificated
Transfer Form for certificated holders, and the Company's ADS
Depositary, Citi, are included on the Company's website at
corporate.abcam.com.
Existing holders of ADSs who do not also hold Ordinary Shares do
not need to take any action in connection with the AIM
Delisting.
If the Resolution is not passed at the General Meeting, all
documents provided to Equiniti or Citi in relation to the deposit
of Ordinary Shares for delivery of ADSs shall be of no effect and
all original share certificates will be returned to shareholders by
Equiniti.
UK tax treatment
The Company cannot and does not provide any form of taxation
advice to shareholders and therefore shareholders are strongly
advised to seek their own taxation advice to confirm the
consequences of continuing to hold unlisted Ordinary Shares or
depositing Ordinary Shares for delivery of ADSs.
The following summary does not constitute legal or tax advice
and is not exhaustive. The Company's understanding of the current
position for individuals who are UK tax resident and UK domiciled
for relevant tax purposes is as follows but it should be noted that
the position on certain points is not free from uncertainty and
that the Company has not taken steps to confirm the current
position with HMRC. Therefore, the following should not be relied
upon by shareholders without taking further advice (and the Company
accepts no liability in respect of any such reliance on any
information provided herein on taxation matters):
-- The AIM Delisting should not, in itself, alter the
classification of the Ordinary Shares in terms of whether these
qualify as unlisted / unquoted securities for the purposes of
certain specific UK tax rules (notably, the UK inheritance tax
business property relief rules), recognising that in October 2020,
the Company completed a direct listing of ADSs on Nasdaq.
Shareholders should be aware that HMRC has not published any
detailed guidance on the treatment of 'ADSs' for inheritance tax
purposes to date.
-- Under HMRC's stated practice, those shareholders who elect to
deposit their holdings of Ordinary Shares for delivery of
Nasdaq-listed ADSs should not be considered as disposing of the
Ordinary Shares for UK capital gains tax purposes when transferring
the shares to the Company's ADS Depositary, Citi, in exchange for
issue of ADSs on the basis that the shareholder retains beneficial
ownership of the Ordinary Shares.
Shareholders who elect to deposit their holdings of Ordinary
Shares for delivery of Nasdaq-listed ADSs prior to the AIM
Delisting should not incur a stamp duty, or SDRT, charge. It is
expected that shareholders who elect to deposit their holdings of
Ordinary Shares for delivery of Nasdaq-listed ADSs following the
AIM Delisting will generally incur a UK stamp duty, or SDRT, charge
at the rate of 1.5 per cent. of the market value of the Ordinary
Shares being deposited.
It is strongly recommended that shareholders obtain appropriate
professional advice in respect of these and other taxes.
Further information in relation to the AIM Delisting
The Board believes that the proposed AIM Delisting is an
appropriate next step for the Company and is in the best interests
of shareholders as a whole. Further information about the process
required to deposit Ordinary Shares for delivery of ADSs tradeable
on Nasdaq, together with a set of Frequently Asked Questions,
accompanies the Circular.
Action to be taken to deposit Ordinary Shares for delivery of
ADSs
Shareholders are reminded that the Company's Ordinary Shares
will continue to be traded on AIM until market close (4.30 p.m.
London time) on 13 December 2022. Any shareholder holding Ordinary
Shares in certificated form who wishes to deposit their holding of
Ordinary Shares for delivery of Nasdaq-listed ADSs prior to the AIM
Delisting must submit their Certificated Transfer Form accompanying
the Circular and their original share certificate(s) to Equiniti,
so as to be received by Equiniti by no later than 5.00 p.m. on 1
December 2022 in accordance with the instructions in the form.
Any shareholder holding shares in CREST who wishes to deposit
their holding of Ordinary Shares for delivery of Nasdaq-listed ADSs
prior to the AIM Delisting should contact their broker as soon as
possible to deposit their Ordinary Shares.
If the Resolution is passed at the General Meeting, after AIM
market close (4.30 p.m. London time) on 13 December 2022, holders
of Ordinary Shares can still hold the Ordinary Shares, but there
will be no public market in the United Kingdom on which the
Ordinary Shares can be traded. It is expected that shareholders who
elect to deposit their holdings of Ordinary Shares for delivery of
Nasdaq listed ADSs following the AIM Delisting will incur a stamp
duty, or SDRT, charge at the rate of 1.5 per cent. of the market
value of the Ordinary Shares being deposited.
If the Resolution is not passed at the General Meeting, all
documents provided to Equiniti or Citi in relation to the deposit
of Ordinary Shares for delivery of ADSs shall be of no effect and
all original share certificates will be returned to shareholders by
Equiniti.
Existing holders of ADSs not also holding Ordinary Shares do not
need to take any action in connection with the AIM Delisting.
In respect of any queries regarding completion of the
Certificated Transfer Form, a shareholder assistance advice line is
being operated by the Company's Receiving Agent, Equiniti, which
can be accessed by all shareholders on +44 (0) 333-207-5963. Calls
are charged at the standard geographic rate and will vary by
provider. Calls from outside the UK will be charged at the
applicable international rate. Lines are open 8.30 a.m. to 5.30
p.m., Monday to Friday, excluding public holidays in England and
Wales.
Application of the City Code following the AIM Delisting
Following the AIM Delisting shareholders will continue to
benefit from the protection afforded by the Companies Act 2006 (as
the Company remains incorporated in England and Wales). In
addition, the Company may benefit from any applicable protections
afforded by virtue of the Nasdaq listing of ADSs, as well as any
applicable rules and regulations of the SEC.
The Panel on Takeovers and Mergers ("Panel") has confirmed to
the Company that following the AIM Delisting, based on the current
composition of the Board, the City Code on Takeovers and Mergers
("City Code") will not apply to the Company. However, the City Code
could apply to the Company in the future if any changes to the
Board composition result in the Panel considering that the Company
has its place of central management and control in the United
Kingdom (or the Channel Islands or the Isle of Man).
The City Code is issued and administered by the Panel. Abcam plc
is a company to which the City Code applies and its shareholders
are accordingly entitled to the protections afforded by the City
Code. The City Code and the Panel operate principally to ensure
that shareholders are treated fairly and are not denied an
opportunity to decide on the merits of a takeover and that
shareholders of the same class are afforded equivalent treatment by
an offeror. The City Code also provides an orderly framework within
which takeovers are conducted. In addition, it is designed to
promote, in conjunction with other regulatory regimes, the
integrity of the financial markets. You can view a copy of the code
at https://www.thetakeoverpanel.org.uk/the-code .
Following the AIM Delisting, as the Company will remain a public
limited company incorporated in England and Wales but its
securities will not be admitted to trading on a regulated market or
multilateral trading facility in the United Kingdom (or a stock
exchange in the Channel Islands or the Isle of Man), the City Code
will only apply to the Company if it is considered by the Panel to
have its place of central management and control in the United
Kingdom (or the Channel Islands or the Isle of Man). This is known
as the "residency test". The way in which the test for central
management and control is applied for the purposes of the City Code
may be different from the way in which it is applied by the United
Kingdom tax authorities, HMRC. Under the City Code, the Panel looks
to where the majority of the directors of the Company are resident,
amongst other factors, for the purposes of determining where the
Company has its place of central management and control.
Shareholders should note that, if the AIM Delisting becomes
effective and the City Code ceases to apply to the Company, they
will not receive the protections afforded by the City Code in the
event that there is a subsequent offer to acquire their shares.
Brief details of the Panel, the City Code and the protections
given by the City Code are described in Appendix A to the Circular.
Before giving your approval to the AIM Delisting, you may want to
take independent professional advice from an appropriate
independent financial adviser.
Shareholder questions
If you would like to ask a question of the Board relating to the
business of the General Meeting, we invite you to send it by email
to Company.Secretary@abcam.com . We will endeavour to respond to
all questions asked via email after the General Meeting. Answers to
common questions asked will also be published on the Company's
website.
The General Meeting
A notice convening the General Meeting, which is to be held at
Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX
United Kingdom at 2.00 p.m. (London time) on 11 November 2022 is
set out at the end of the Circular. At the General Meeting, the
Resolution will be proposed as a special resolution.
Recommendation
Your Board believes that the resolution contained in the Notice
of Meeting is in the best interests of the Company and its
shareholders as a whole. Accordingly, the Board unanimously
recommends that shareholders vote in favour of the resolution to be
proposed at the General Meeting, as the Company's Directors intend
to do in respect of their own beneficial shareholdings in the
Company.
Expected Timetable
Dispatch of the Circular and the accompanying 17 October 2022
documents
Latest date for receipt of proxy voting 2.00 p.m. on 9 November 2022
instructions and (if applicable) hard copy
forms of proxy
General Meeting 2.00 p.m. on 11 November 2022
Last date for receipt by the Registrar 5.00 p.m. on 1 December 2022
from certificated shareholders of duly
completed Certificated Transfer Forms and
original share certificates
Latest date for receipt by the Depositary 5.00 p.m. on 1 December 2022
from CREST holders of duly completed issuance
forms
Expected date for issuance of ADSs to block 12 December 2022
transfer participants
Expected date of mailing of ADS confirmations 13 December 2022
to shareholders by the Depositary
Last day of dealings in the Ordinary Shares 13 December 2022
on AIM
Cancellation of admission to trading on 7.00 a.m. on 14 December 2022
AIM of the Ordinary Shares
_______
Notes
(1) References to time in this announcement are to London time unless otherwise stated.
(2) Each of the times and dates in the above timetable are
subject to change. If any of the above times and/or dates change,
the revised times and/or dates will be notified to shareholders by
announcement through a Regulatory Information Service.
(3) All steps after the General Meeting are dependent on the
Resolution being passed at the General Meeting. If the Resolution
is not passed at the General Meeting, all documents provided to the
Registrar and/or the Depositary in relation to the deposit of
Ordinary Shares for delivery of ADSs shall be of no effect and all
original share certificates will be returned to shareholders by the
Registrar.
Disclaimer
This announcement contains inside information as defined for the
purposes of Article 7 of Regulation (EU) no. 596/2014, as it forms
part of domestic law in the United Kingdom by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR").
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Ordinary Shares or ADSs, nor
shall there be any sale of the Ordinary Shares or ADSs in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
Neither this announcement nor the Circular forms part of an
offer of transferable securities to the public in the United
Kingdom and no prospectus has been, or is required to be, submitted
to the FCA for approval.
Numis Securities Limited, which is a member of the London Stock
Exchange, is authorised and regulated in the UK by the Financial
Conduct Authority and is acting as nominated adviser to the Company
and no one else for the purposes of the AIM Rules in connection
with the AIM Delisting. Numis is not acting for, and will not be
responsible to, any person other than the Company for providing the
protections afforded to its customers or for advising any other
person on the contents of this announcement or the AIM Delisting.
Numis is not responsible for the contents of this announcement.
Numis' responsibilities as the Company's nominated adviser under
the AIM Rules are owed solely to the London Stock Exchange and are
not owed to the Company, any Director, or to any other person.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding the implications of the AIM Delisting on the
trading of the Company's equity securities and related timing, as
well as statements that include the words "expect," "intend,"
"plan," "believe," "project," "forecast, " "estimate," "may,"
"should," "anticipate" and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation: the risk that
anticipated trading volume in the Company's equity securities on
Nasdaq may not materialise; and the important factors discussed
under the caption "Risk Factors" in Abcam's Annual Report on Form
20-F for the year ended 31 December 2021, which is on file with the
U.S. Securities and Exchange Commission ("SEC") and is available on
the SEC website at www.sec.gov, as such factors may be updated from
time to time in Abcam's other filings with the SEC. Any
forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
Enquiries:
Abcam plc
Alan Hirzel, Chief Executive Officer
Michael Baldock, Chief Financial Officer
Tommy J. Thomas, CPA, Vice President, Investor +44 (0) 1223 696
Relations 000
Numis - Nominated Advisor & Joint Corporate
Broker + 44 (0) 20 7260
Freddie Barnfield / Duncan Monteith 1000
Morgan Stanley - Joint Corporate Broker + 44 (0) 20 7425
Tom Perry / Luka Kezic 8000
FTI Consulting + 44 (0) 20 3727
Ben Atwell / Julia Bradshaw / Lydia Jenkins 1000
About Abcam
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways. Already a pioneer in data
sharing and ecommerce in the life sciences, Abcam's ambition is to
be the most influential company in life sciences by helping advance
global understanding of biology and causes of disease, which, in
turn, will drive new treatments and improved health. Abcam's
worldwide customer base of approximately 750,000 life science
researchers uses Abcam's antibodies, reagents, biomarkers and
assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent program of customer reviews and
datasheets, combined with industry-leading validation initiatives,
gives researchers increased confidence in their results. Founded in
1998 and headquartered in Cambridge, UK, the Company has served
customers in more than 130 countries. Abcam's ordinary shares are
listed on the London Stock Exchange (AIM: ABC) and its American
Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq:
ABCM).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXEKFESAFFA
(END) Dow Jones Newswires
October 17, 2022 02:00 ET (06:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Abcam (LSE:ABC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
